Skip to main content
OpenTrials
Completed

NCT Number: NCT01738503

Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects

This is an open-label study in treatment seeking opioid-dependent subjects for safety, tolerability, pharmacokinetics (PK), efficacy markers, and opioid receptor availability of subcutaneous injections of depot buprenorphine after induction and stabilization of treatment seeking subjects onto Subutex.

Subjects were planned to receive 4 subcutaneous (SC) injections of RBP-6000 separated by 28 days (Cohorts 1-5) or 6 SC injections of RBP-6000 separated by 28 days (Cohort 6) after a 13-day induction and dose stabilisation period on SUBUTEX Sublingual (SL) tablet at dose levels of 8-24 mg.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Opioid Related Disorder Chemically-Induced Disorders Mental Disorders Narcotic-Related Disorders Opioid-Related Disorders Substance-Related Disorders

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Vince and Associates Clinical Research

Overland Park, Kansas, 66212, United States

About this study

  • Open-label SUBUTEX Sublingual Tablet Induction and Stabilisation Period After completing the screening period, subjects entered an open-label SUBUTEX SL tablet induction and stabilisation period to achieve stable daily doses of 8 mg, 12 mg, 14 mg, 24 mg or 8 - 24 mg (variable) during a 13 day inpatient (Day -14 to Day -1) period.
  • Open-label Treatment Phase On Day 1, eligible subjects discontinued use of SUBUTEX SL tablet and received a subcutaneous (SC) injection of RBP-6000. The dose of RBP-6000 received and the cohort to which a subject was assigned depended upon the SUBUTEX SL tablet dose on Day -1.
  • Injection 1 (Day 1): 3 days inpatient post-dose (Day 1 to Day 3) and outpatient visits (Day 4 to Day 28); serial pharmacokinetic (PK) samples
  • Injection 2 (Day 29): 60-hour inpatient pre-dose and post-dose (Day 28 to Day 31) and outpatient visits (Day 32 to Day 56); sparse PK samples
  • Injection 3 (Day 57): 60-hour inpatient pre-dose and post-dose (Day 56 to Day 59) and outpatient visits (Day 60 to Day 84); sparse PK samples
  • Injection 4 (Day 85): 60-hour inpatient pre-dose and post-dose (Day 84 to Day 87) and outpatient visits (Day 88 to Day 113 [or Day 112 for Cohort 6]); serial PK samples
  • Cohort 6 ONLY: Injection 5 (Day 113): 60-hour inpatient pre-dose and post-dose (Day 112 to Day 115) and outpatient visits (Day 116 to Day 140); serial PK samples
  • Cohort 6 ONLY: Injection 6 (Day 141): 60-hour inpatient pre- and post-dose (Day 140 to Day 143) and outpatient visits (Day 144 to Day 169); serial PK samples
  • Safety Follow-up: weekly visits up to 60 days post-Injection 4 (PK Day 114 to Day 141) for subjects in Cohorts 1-5 who did not take part in the positron emission tomography (PET) imaging sub-study and up to 60 days post-Injection 6 (PK Day 169 to Day 197) for subjects in Cohort 6

The objective of the PET imaging sub-study was to evaluate the relationship between buprenorphine plasma levels and the ability of the 200 mg and 300 mg doses of RBP-6000 to reduce mu-opioid receptor availability measured with [11C]carfentanil and positron emission tomography (PET) scans. This objective was exploratory in nature and results are not reported as part of these summary results.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female subjects
  • Agree not to take any buprenorphine products other than those administered for the current study throughout participation in the study
  • Body mass index (BMI) of >18.0 to < 33.0 kg/m

Exclusion criteria

  • Participants with a current diagnosis requiring chronic opioid treatment
  • Participants with a history of risk factors of Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) or an ECG demonstrating a Fridericia's corrected QT interval (QTcF) >450 msec in males and QTcF > 470 in females at screening
  • Abuse of buprenorphine or use of buprenorphine within 14 days of informed consent

Treatment and study plan

RBP-6000

Drug

18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.

Other names: buprenorphine

Subutex

Drug

Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.

Other names: buprenorphine

Primary outcomes

  1. Participants With Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Days -14 to -1 (Subutex treatment), Days 1-316 (RBP-6000 treatment)

    TEAE=any untoward medical occurrence that develops or worsens in severity after dispensation of the study drug and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= a marked limitation in activity. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent one of the outcomes listed in this definition. A serious AE (SAE) is defined as any AE occurring at any dose that results in any of the following outcomes: death; lifethreatening AE; hospitalization or prolongation of existing hospitalization; a persistent or significant disability/incapacit

  2. Buprenorphine PK: % Fluctuation

    Time frame: Day -1, Days 1-29, 85-113, 141-197

    % Fluctuation was defined as the degree of fluctuation of buprenorphine plasma concentrations calculated as (Cmax-Cmin)/Cavg*100, expressed as a percentage. Cmax=maximum plasma concentration Cmin=minimum plasma concentration Cavg = average plasma concentration

    Results are reported across three timeframes:

    • Sublingual Period (Day -1 dose of SUBUTEX): a steady-state reading.
    • Plateau Parameters (Days 3-29 relative to RBP-6000 injections 1, 4 and 6)
    • Overall Parameters (Days 1-29 relative to RBP-6000 injections 1, 4 and 6)

    The PK sampling schedule was

    • hour 0 (predose) on days -7 to -1,
    • hours 0.5, 1,2,4,6, 8,12, 24 post-dose on Day -1
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672 post injections 1 and 4
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672, 846, 1008, 1200, 1344 post injection 6

  3. Buprenorphine PK: Area Under Plasma Concentration Time Curves (AUC)

    Time frame: Day -1, Days 1-29, 85-113, 141-197

    AUC calculated using the linear trapezoidal rule and requiring a minimum of 5 data points for each time range.

    Results are reported across four timeframes:

    • Sublingual Period (Day -1 dose of SUBUTEX): a steady-state reading at hours 0-24.
    • Initial Burst Parameters (Days 1-2 relative to RBP-6000 injections 1, 4 and 6) at hours 0-48
    • Plateau Parameters (Days 3-29 relative to RBP-6000 injections 1, 4 and 6) at hours 48-672
    • Overall Parameters (Days 1-29 relative to RBP-6000 injections 1, 4 and 6) at hours 0-24, hours 0-672

    The PK sampling schedule was

    • hour 0 (predose) on days -7 to -1,
    • hours 0.5, 1,2,4,6, 8,12, 24 post-dose on Day -1
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672 post injections 1 and 4
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672, 846, 1008, 1200, 1344 post injection 6

  4. Buprenorphine PK: Average Plasma Concentration (Cavg)

    Time frame: Day -1, Days 1-29, 85-113, 141-197

    Cavg was defined as the AUC (timeframe)/timeframe. For example, the sublingual steady-state Cavg reading on Day -1 = AUC0-24/ 24 hours

    Results are reported across three timeframes:

    • Sublingual Period (Day -1 dose of SUBUTEX): a steady-state reading.
    • Plateau Parameters (Days 3-29 relative to RBP-6000 injections 1, 4 and 6)
    • Overall Parameters (Days 1-29 relative to RBP-6000 injections 1, 4 and 6)

    The PK sampling schedule was

    • hour 0 (predose) on days -7 to -1,
    • hours 0.5, 1,2,4,6, 8,12, 24 post-dose on Day -1
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672 post injections 1 and 4
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672, 846, 1008, 1200, 1344 post injection 6

  5. Buprenorphine PK: Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day -1, Days 1-29, 85-113, 141-197

    Maximum observed plasma concentration, determined directly from individual concentration time data.

    Results are reported across four timeframes:

    • Sublingual Period (Day -1 dose of SUBUTEX): a steady-state reading at hours 0-24.
    • Initial Burst Parameters (Days 1-2 relative to RBP-6000 injections 1, 4 and 6) at hours 0-48
    • Plateau Parameters (Days 3-29 relative to RBP-6000 injections 1, 4 and 6) at hours 48-672
    • Overall Parameters (Days 1-29 relative to RBP-6000 injections 1, 4 and 6)

    The PK sampling schedule was

    • hour 0 (predose) on days -7 to -1,
    • hours 0.5, 1,2,4,6, 8,12, 24 post-dose on Day -1
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672 post injections 1 and 4
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672, 846, 1008, 1200, 1344 post injection 6

  6. Buprenorphine PK: Minimum Observed Plasma Concentration (Cmin)

    Time frame: Day -1, Days 1-29, 85-113, 141-197

    Minimum observed plasma concentration, determined directly from individual concentration time data.

    Results are reported across three timeframes:

    • Sublingual Period (Day -1 dose of SUBUTEX): a steady-state reading at hours 0-24.
    • Plateau Parameters (Days 3-29 relative to RBP-6000 injections 1, 4 and 6) at hours 48-672
    • Overall Parameters (Days 1-29 relative to RBP-6000 injections 1, 4 and 6)

    The PK sampling schedule was

    • hour 0 (predose) on days -7 to -1,
    • hours 0.5, 1,2,4,6, 8,12, 24 post-dose on Day -1
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672 post injections 1 and 4
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672, 846, 1008, 1200, 1344 post injection 6

  7. Buprenorphine PK: Swing of Plasma Concentrations

    Time frame: Day -1, Days 1-29, 85-113, 141-197

    The swing of buprenorphine plasma concentrations calculated as (Cmax-Cmin)/Cmin within the dosing interval.

    Cmax=maximum plasma concentration Cmin=minimum plasma concentration

    Results are reported across three timeframes:

    • Sublingual Period (Day -1 dose of SUBUTEX): a steady-state reading.
    • Plateau Parameters (Days 3-29 relative to RBP-6000 injections 1, 4 and 6)
    • Overall Parameters (Days 1-29 relative to RBP-6000 injections 1, 4 and 6)

    The PK sampling schedule was

    • hour 0 (predose) on days -7 to -1,
    • hours 0.5, 1,2,4,6, 8,12, 24 post-dose on Day -1
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672 post injections 1 and 4
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672, 846, 1008, 1200, 1344 post injection 6

  8. Buprenorphine PK: Time to Maximum Buprenorphine Plasma Concentration (Tmax)

    Time frame: Day -1, Days 1-29, 85-113, 141-197

    Results are reported across four timeframes:

    • Sublingual Period (Day -1 dose of SUBUTEX): a steady-state reading at hours 0-24.
    • Initial Burst Parameters (Days 1-2 relative to RBP-6000 injections 1, 4 and 6) at hours 0-48
    • Plateau Parameters (Days 3-29 relative to RBP-6000 injections 1, 4 and 6) at hours 48-672
    • Overall Parameters (Days 1-29 relative to RBP-6000 injections 1, 4 and 6) at hours 0-24, hours 0-672

    The PK sampling schedule was

    • hour 0 (predose) on days -7 to -1,
    • hours 0.5, 1,2,4,6, 8,12, 24 post-dose on Day -1
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672 post injections 1 and 4
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672, 846, 1008, 1200, 1344 post injection 6

  9. Buprenorphine PK: Accumulation Index in Terms of Area Under the Curve (Rac(AUC))

    Time frame: Days 1-28, 85-113

    Accumulation index in terms of AUC calculated as ratio of AUCtau Injection 4/ AUCtau Injection 1. AUCtau = area under plasma concentration time curve over the dosing interval tau (for SC RBP-6000, tau=28 days).

  10. Buprenorphine PK: Accumulation Index in Terms of Maximum Observed Plasma Drug Concentration (Rac(Cmax))

    Time frame: Days 1-28, 85-113

    Accumulation index in terms of Cmax calculated as ratio of Cmax Injection 4/ Cmax Injection 1.

  11. Buprenorphine PK: Apparent Clearance at Steady-State (CLss/F) Following Injections 4 and 6

    Time frame: Days 85-113, 141-169

    Apparent clearance at steady-state (CLss/F) = Dose / AUCtau (tau was 28 days).

  12. Buprenorphine PK: Area Under Plasma Concentration Time Curve From Time Zero Of Injection 4 (AUC0-∞)

    Time frame: Days 85-113

    Area under plasma concentration time curve from time zero of Injection 4 extrapolated to infinity; calculated for Injection 4 (last injection) in subjects not participating in PET imaging sub-study only as:

    (AUC0-∞ was reported if the coefficient of determination R2 was at least 0.8 and the extrapolated area is less than 25%). A minimum of 5 data points was required. AUC up to the last measurable concentration (AUClast) was calculated by using the linear trapezoidal rule.

  13. Buprenorphine PK: Terminal Phase Half Life (t1/2) Calculated For Injection 4

    Time frame: Days 85-113

    The terminal phase half life calculated for Injection 4 in subjects not participating in PET imaging sub-study. The t1/2 was reported only if the coefficient of determination R2 was at least 0.8.

  14. Norbuprenorphine PK: % Fluctuation

    Time frame: Day -1, Days 1-29, 85-113, 141-197

    % Fluctuation was defined as the degree of fluctuation of norbuprenorphine plasma concentrations calculated as (Cmax-Cmin)/Cavg*100, expressed as a percentage. Cmax=maximum plasma concentration Cmin=minimum plasma concentration Cavg = average plasma concentration

    Results are reported across three timeframes:

    • Sublingual Period (Day -1 dose of SUBUTEX): a steady-state reading.
    • Plateau Parameters (Days 3-29 relative to RBP-6000 injections 1, 4 and 6)
    • Overall Parameters (Days 1-29 relative to RBP-6000 injections 1, 4 and 6)

    The PK sampling schedule was

    • hour 0 (predose) on days -7 to -1,
    • hours 0.5, 1,2,4,6, 8,12, 24 post-dose on Day -1
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672 post injections 1 and 4
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672, 846, 1008, 1200, 1344 post injection 6

  15. Norbuprenorphine PK: Area Under Plasma Concentration Time Curves (AUC)

    Time frame: Day -1, Days 1-29, 85-113, 141-197

    AUC calculated using the linear trapezoidal rule and requiring a minimum of 5 data points for each time range.

    Results are reported across four timeframes:

    • Sublingual Period (Day -1 dose of SUBUTEX): a steady-state reading at hours 0-24.
    • Initial Burst Parameters (Days 1-2 relative to RBP-6000 injections 1, 4 and 6) at hours 0-48
    • Plateau Parameters (Days 3-29 relative to RBP-6000 injections 1, 4 and 6) at hours 48-672
    • Overall Parameters (Days 1-29 relative to RBP-6000 injections 1, 4 and 6) at hours 0-24, hours 0-672

    The PK sampling schedule was

    • hour 0 (predose) on days -7 to -1,
    • hours 0.5, 1,2,4,6, 8,12, 24 post-dose on Day -1
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672 post injections 1 and 4
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672, 846, 1008, 1200, 1344 post injection 6

  16. Norbuprenorphine PK: Average Plasma Concentration (Cavg)

    Time frame: Day -1, Days 1-29, 85-113, 141-197

    Cavg was defined as the AUC (timeframe)/timeframe. For example, the sublingual steady-state Cavg reading on Day -1 = AUC0-24/ 24 hours

    Results are reported across three timeframes:

    • Sublingual Period (Day -1 dose of SUBUTEX): a steady-state reading.
    • Plateau Parameters (Days 3-29 relative to RBP-6000 injections 1, 4 and 6)
    • Overall Parameters (Days 1-29 relative to RBP-6000 injections 1, 4 and 6)

    The PK sampling schedule was

    • hour 0 (predose) on days -7 to -1,
    • hours 0.5, 1,2,4,6, 8,12, 24 post-dose on Day -1
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672 post injections 1 and 4
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672, 846, 1008, 1200, 1344 post injection 6

  17. Norbuprenorphine PK: Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day -1, Days 1-29, 85-113, 141-197

    Maximum observed plasma concentration, determined directly from individual concentration time data.

    Results are reported across four timeframes:

    • Sublingual Period (Day -1 dose of SUBUTEX): a steady-state reading at hours 0-24.
    • Initial Burst Parameters (Days 1-2 relative to RBP-6000 injections 1, 4 and 6) at hours 0-48
    • Plateau Parameters (Days 3-29 relative to RBP-6000 injections 1, 4 and 6) at hours 48-672
    • Overall Parameters (Days 1-29 relative to RBP-6000 injections 1, 4 and 6)

    The PK sampling schedule was

    • hour 0 (predose) on days -7 to -1,
    • hours 0.5, 1,2,4,6, 8,12, 24 post-dose on Day -1
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672 post injections 1 and 4
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672, 846, 1008, 1200, 1344 post injection 6

  18. Norbuprenorphine PK: Minimum Observed Plasma Concentration (Cmin)

    Time frame: Day -1, Days 1-29, 85-113, 141-197

    Minimum observed plasma concentration, determined directly from individual concentration time data.

    Results are reported across three timeframes:

    • Sublingual Period (Day -1 dose of SUBUTEX): a steady-state reading at hours 0-24.
    • Plateau Parameters (Days 3-29 relative to RBP-6000 injections 1, 4 and 6) at hours 48-672
    • Overall Parameters (Days 1-29 relative to RBP-6000 injections 1, 4 and 6)

    The PK sampling schedule was

    • hour 0 (predose) on days -7 to -1,
    • hours 0.5, 1,2,4,6, 8,12, 24 post-dose on Day -1
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672 post injections 1 and 4
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672, 846, 1008, 1200, 1344 post injection 6

  19. Norbuprenorphine PK: Swing of Plasma Concentrations

    Time frame: Day -1, Days 1-29, 85-113, 141-197

    The swing of norbuprenorphine plasma concentrations calculated as (Cmax-Cmin)/Cmin within the dosing interval.

    Cmax=maximum plasma concentration Cmin=minimum plasma concentration

    Results are reported across three timeframes:

    • Sublingual Period (Day -1 dose of SUBUTEX): a steady-state reading.
    • Plateau Parameters (Days 3-29 relative to RBP-6000 injections 1, 4 and 6)
    • Overall Parameters (Days 1-29 relative to RBP-6000 injections 1, 4 and 6)

    The PK sampling schedule was

    • hour 0 (predose) on days -7 to -1,
    • hours 0.5, 1,2,4,6, 8,12, 24 post-dose on Day -1
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672 post injections 1 and 4
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672, 846, 1008, 1200, 1344 post injection 6

  20. Norbuprenorphine PK: Time to Maximum Buprenorphine Plasma Concentration (Tmax)

    Time frame: Day -1, Days 1-29, 85-113, 141-197

    Results are reported across four timeframes:

    • Sublingual Period (Day -1 dose of SUBUTEX): a steady-state reading at hours 0-24.
    • Initial Burst Parameters (Days 1-2 relative to RBP-6000 injections 1, 4 and 6) at hours 0-48
    • Plateau Parameters (Days 3-29 relative to RBP-6000 injections 1, 4 and 6) at hours 48-672
    • Overall Parameters (Days 1-29 relative to RBP-6000 injections 1, 4 and 6) at hours 0-24, hours 0-672

    The PK sampling schedule was

    • hour 0 (predose) on days -7 to -1,
    • hours 0.5, 1,2,4,6, 8,12, 24 post-dose on Day -1
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672 post injections 1 and 4
    • hours 0 (pre-dose) 1, 2, 4, 6, 8, 12, 20, 24, 25, 26, 28, 30, 32, 36, 44, 48, 144, 192, 240, 312, 384, 456, 528, 600, 672, 846, 1008, 1200, 1344 post injection 6

  21. Norbuprenorphine PK: Accumulation Index in Terms of Area Under the Curve (Rac(AUC))

    Time frame: Days 1-28, 85-113

    Accumulation index in terms of AUC calculated as ratio of AUCtau Injection 4/ AUCtau Injection 1. AUCtau = area under plasma concentration time curve over the dosing interval tau (for SC RBP-6000, tau=28 days).

  22. Norbuprenorphine PK: Accumulation Index in Terms of Maximum Observed Plasma Drug Concentration (Rac(Cmax))

    Time frame: Days 1-28, 85-113

    Accumulation index in terms of Cmax calculated as ratio of Cmax Injection 4/ Cmax Injection 1.

  23. Norbuprenorphine PK: Area Under Plasma Concentration Time Curve From Time Zero Of Injection 4 and 6 (AUC0-∞)

    Time frame: Days 85-113, 141-197

    Area under plasma concentration time curve from time zero of Injection 4 extrapolated to infinity; calculated for Injection 4 and 6 (last injection) in subjects not participating in PET imaging sub-study only as:

    (AUC0-∞ was reported if the coefficient of determination R2 was at least 0.8 and the extrapolated area is less than 25%). A minimum of 5 data points was required. AUC up to the last measurable concentration (AUClast) was calculated by using the linear trapezoidal rule.

  24. Norbuprenorphine PK: Terminal Phase Half Life (t1/2) Calculated For Injection 4

    Time frame: Days 85-113, 141-197

    The terminal phase half life calculated for Injection 4 in subjects not participating in PET imaging sub-study. The t1/2 was reported only if the coefficient of determination R2 was at least 0.8.

Secondary outcomes

  1. Change From Baseline in the Clinical Opiate Withdrawal Scale (COWS) Prior to Injections 1, 2, 3, 4 and 6

    Time frame: Baseline (screening to Day -13), Days -1, 1, 29, 57, 85 141

    COWS is an 11-item instrument used to assess symptoms of opioid withdrawal (Wesson et al., 1999). The score is the sum of the responses for a total range of 0-48. The COWS is commonly used by clinicians treating patients with buprenorphine to monitor the severity of withdrawal. COWS scores below 5 are considered not indicative of withdrawal. Scores from 5 to 12 are considered mild withdrawal; from 13 to 24 moderate withdrawal; 25 to 36 moderate/severe withdrawal, and 37-48 severe withdrawal. Each participant was to be assessed by the same qualified and trained individuals throughout the course of the study as much as possible.

    Baseline was defined as the peak (maximum) value from screening to study Day -13 pre-SUBUTEX dose. The baseline score is reported as the mean of observed values. Other measurements were taken prior to dosing and reported as change from baseline values.

    Negative change from baseline values indicate a lessening of withdrawal symptoms.

  2. Change From Baseline in the Subjective Opiate Withdrawal Scale (SOWS) Prior to Injections 1, 2, 3, 4 and 6

    Time frame: Baseline (screening to Day -13), Days -1, 1, 29, 57, 85 141

    The Subjective Opiate Withdrawal Scale (SOWS) contains 16 symptoms whose intensity the participant rates on a scale of 0 (not at all) to 4 (extremely) for a full scale of 0 (no withdrawal symptoms) to 64 (extreme withdrawal symptoms).

    Baseline was defined as the peak (maximum) value from screening to study Day -13 pre-SUBUTEX dose. The baseline score is reported as the mean of observed values. Other measurements were taken prior to dosing and reported as change from baseline values.

    Negative change from baseline values indicate a lessening of withdrawal symptoms.

  3. Change From Baseline in the Clinical Opioid Craving Visual Analog Scale (VAS) Total Score Prior to Injections 1, 2, 3, 4 and 6

    Time frame: Baseline (screening to Day -13), Days -1, 1, 29, 57, 85 141

    The Total Score was the sum of 10 questions regarding cravings each ranging from 0 (no craving) - 10 (extreme craving) for a total range from 0 (no cravings") to 100 ("most intense craving I have ever had").

    Baseline was defined as the peak (maximum) value from screening to study Day -13 pre-SUBUTEX dose. The baseline score is reported as the mean of observed values. Other measurements were taken prior to dosing and reported as change from baseline values.

    Negative change from baseline values indicate a lessening of craving symptoms.

  4. Change From Baseline in the Clinical Global Impression Severity (CGI-S) Scale on Days 1, 7, 29, 57, 85 and 141

    Time frame: Baseline (screening Day -15), Days 1, 7, 29, 57, 85, 141

    The CGI-S is a 7-item scale completed by the clinician used to rate the severity of symptoms. The total range is 1 (normal, not at all ill) to 7 (most extremely ill).

    Baseline was defined as value from screening (Day -13). The baseline score is reported as the mean of observed values. Other measurements were taken prior to dosing (not applicable for Day 7) and reported as change from baseline values.

    Negative change from baseline values indicate a lessening of the severity of symptoms.

  5. Change From Baseline in the Clinical Global Impression Improvement (CGI-I) Scale on Days 7, 29, 57, 85 and 141

    Time frame: Baseline (Day 1), Days 7, 29, 57, 85, 141

    The CGI-I is a 7-item scale completed by the clinician used to rate their impression of how much the participant has improved over a baseline state. The total range is 1 (very much improved) to 7 (very much worse).

    Baseline was defined as value from Day 1. The baseline score is reported as the mean of observed values. Other measurements were taken prior to dosing (not applicable for Day 7) and reported as change from baseline values.

    Negative change from baseline values indicate an improvement.

  6. Columbia Suicide Severity Rating Scale (C-SSRS): Severity

    Time frame: Screening (summary of lifetime), Screening (last 6 months), Day 65, Day 113, End of Study (up to day 365)

    The scale used in the C-SSRS is a continuous variable ranging from 0 (no suicidal ideation present) to 5 (active ideation with specific plan and intent). Only participants with suicidal ideation (scale of 1-5) are reported. 1=desire to be dead to 5=active ideation with specific plan and intent.

  7. Percentage of Urine Drug Screen Samples Negative for Opioids

    Time frame: Day 1 to End of Study (up to day 365)

    Urine samples were screened for the following drugs:

    • opiates
    • cocaine
    • amphetamines
    • methadone
    • cannabinoids
    • barbiturates
    • buprenorphine. Buprenorphine was only included in the urine drug screen at screening and Day -14 to determine if the subject had used any buprenorphine-containing products prior to the start of SUBUTEX SL tablet dosing.
    • benzodiazepines
    • methamphetamine
    • phencyclidine

    Urine drug screens were run every day when the participant was an inpatient; every 2-3 days when the participant was an outpatient. Drug screens were run less often for those participants in the PET substudy.

Sponsors and collaborators

Lead sponsor

Indivior Inc.

Industry

Registry information

Official study title

Open-Label, Multicenter, Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, Efficacy Markers, and Opioid Receptor Availability of Subcutaneous Injections of Depot Buprenorphine in Treatment Seeking Opioid-Dependent Subjects

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Nov 30, 2012
Registry last updated
Feb 23, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.